Purpose: The role of consolidation chemoradiation (CCRT) after systemic chemotherapy in locally advanced pancreatic cancer (LAPC) is still controversial. We aim to evaluate the effectiveness of CCRT in LAPC using systematic review and meta-analysis of prospective studies. Materials and Methods: Prospective clinical trials of LAPC receiving chemotherapy with or without subsequent CCRT were included in the analysis. We systematically searched in PubMed, Medline, Embase, Web of Science. The primary outcome of interest was one-year survival. Secondary endpoints were median overall survival, progression-free survival, toxicity, and resection rate. Results: Forty-one studies with forty-nine study arms were included with a total of 1,018 patients receiving CCRT after induction chemotherapy (ICT) and 954 patients receiving chemotherapy alone. CCRT after ICT did not improve one-year survival significantly in LAPC patients compared with chemotherapy alone (58% vs 52%). ICT lasted for at least three months revealed significantly improved survival of additional CCRT to LAPC patients compared to chemotherapy alone (65% vs 52%). A marginal survival benefit of consolidation CCRT was noted in studies using maintenance chemotherapy (59% vs 52%), and fluorouracil-based CCRT (64% vs 52%), as well as in studies conducted after the 2010 (64% vs 55%). Conclusions: The survival benefit of ICT+CCRT over chemotherapy alone in treating LAPC was noted when ICT lasted for at least three months. Fluorouracil-based CCRT, and maintenance chemotherapy were associated with improved clinical outcomes.
Date:
2018-04
Relation:
Cancer Research and Treatment. 2018 Apr;50(2):562-574.
